amylin glp-1 dual agonist Media Centre Amylin Revisited: A 5-Year Perspective

The clinically most relevant and important action of DPP-4 inhibitors is the endogenous elevation of the incretin hormone concentration of GLP-1 that consecutively leads to a glucose-dependent stimulation of insulin secretion and an inhibition of glucagon secretion (10)

While these drugs are designed for long-term use in disease management, many individuals use GLP-1s for a limited periodeither to jump-start weight loss before transitioning to a lifestyle-based maintenance or due to financial constraints

mental illness or eating disorders

Three-year follow-up data showed that this weight loss was largely sustained over the longer term

Neuropsychiatr Dis Treat (2020) 16:181725